The path a new drug takes from discovery to commercialization is a long one – and is never a guaranteed success. Biopharmaceuticals are very susceptible to contamination, and contamination of just one batch - whether a development batch or a commercial scale batch – can bring the process to a screeching halt.
Avoiding contamination of a process and product from mycoplasma is of utmost importance to manufacturers and regulators alike. State-of-the-art mycoplasma detection kits are available to mitigate the chance of a contamination event. Download this free infographic to learn about the five guidelines you should consider when choosing the appropriate mycoplasma detection kit for your application.
